

ABSTRACT OF THE DISCLOSURE

The present disclosure, as a composition for sustained-release injection comprising deslorelin, can prevent initial over-release by adjusting the release rate of deslorelin at a target site and can exhibit the effect of deslorelin for 1 month or more by
5 being exposed in an amount enough to show the effect of deslorelin.

Further, the microparticles can prepare microparticles that have a uniform particle size and are capable of exhibiting the effect of continuously releasing deslorelin for a long time.

10 FIG. 1